JAM
HRTX icon

JW Asset Management’s Heron Therapeutics HRTX Stock Holding History

JW Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3M Buy
3,751,073
+80,000
+2% +$92.7K 1.23% 11
2025
Q4 		$4.77M Buy
3,671,073
+378,440
+11% +$467K 1.55% 10
2025
Q3 		$4.15M Buy
3,292,633
+954,890
+41% +$1.51M 1.99% 8
2025
Q2 		$4.84M Hold
2,337,743
– – 2.39% 7
2025
Q1 		$5.14M Buy
2,337,743
+45,325
+2% +$88K 2.91% 5
2024
Q4 		$3.51M Hold
2,292,418
– – 1.67% 7
2024
Q3 		$4.56M Hold
2,292,418
– – 2.06% 7
2024
Q2 		$8.02M Hold
2,292,418
– – 3.31% 6
2024
Q1 		$6.35M Hold
2,292,418
– – 2.32% 10
2023
Q4 		$3.9M Sell
2,292,418
-115,000
-5% -$127K 2.22% 9
2023
Q3 		$2.48M Buy
2,407,418
+200,000
+9% +$285K 1.07% 9
2023
Q2 		$2.56M Buy
+2,207,418
New +$3.94M 0.93% 7
2015
Q1 		– Sell
-3,275
Closed -$33K – 50
2014
Q4 		$33K Buy
+3,275
New +$26.7K 0.02% 53

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

JW Asset Management's HRTX Position: Q1 2026 in Review

JW Asset Management increased its Heron Therapeutics (HRTX) stake by 2.2% in Q1 2026, buying an estimated $92.7K and bringing the position to 3,751,073 shares worth $3M. The position accounts for 1.23% of the portfolio, ranked #11.

JW Asset Management first reported a position in HRTX in Q4 2014 and has held it in 13 quarters since. The position peaked at $8.02M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • JW Asset Management held 3,751,073 shares of Heron Therapeutics worth $3M as of Q1 2026.
  • JW Asset Management bought 80,000 Heron Therapeutics shares in Q1 2026, an estimated $92.7K.
  • Heron Therapeutics made up 1.23% of JW Asset Management's portfolio in Q1 2026, its #11 holding.
  • JW Asset Management first reported a position in Heron Therapeutics in Q4 2014 and has held it in 13 quarters since.
  • JW Asset Management's Heron Therapeutics position peaked at $8.02M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on JW Asset Management's 13F filing for Q1 2026, filed 8 May 2026.